News
IDIBELL and ICO turn pink for Breast Cancer World Day
Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) will join the pink movement associated with the celebration of Breast Cancer World Day. Thus, the facade of the Duran i Reynals Hospital (Granvia de l’Hospitalet 199-203) will turn pink, the night of Friday, October 19th, World Day Against Breast Cancer, to remember the importance of early […]
New scientific-technical equipment for IDIBELL
The Spanish ministry of science, innovation and universities has awarded IDIBELL a grant (EQC2018-005246-P) worth approximately 93000€ to purchase a Seahorse 96, a high-throughput equipment for cellular metabolism and mitochondrial function analysis. This grant belongs to the 2018 call for the acquisition of scientific-technical equipment within the National R&D&I Plan 2017-2020.
New therapeutic strategies for breast cancer
The risk of developing breast cancer is largely determined by the ability of the cells to repair damage to their DNA and, at the same time, by the regulation of the “stem cells” that may eventually become tumors. However, it is unknown how these two fundamental processes co-regulate. In a recent study, IDIBELL – […]
Statement on Dr Manel Esteller leaving IDIBELL
The Bellvitge Biomedical Research Institute (IDIBELL) states that Dr Manel Esteller, ICREA researcher, professor at the University of Barcelona, and until now, coordinator of the Epigenetics and Cancer Biology Program (PEBC) at IDIBELL, has been appointed director of the Josep Carreras Leukaemia Research Institute, a position that implies the termination of his employment relationship with […]
400,000 dollars to fight prostate cancer
Dr. Álvaro Aytés (IDIBELL – ICO / ProCure) project receives an Idea Development Award from the American Department of Defense (DoD) within its Prostate Cancer Research Program.
Bioinformatics deciphers the metabolic characteristics of 25 types of cancer
Thanks to a bioinformatics analysis of 9,428 tumor samples, vulnerabilities potentially leading to new, more precise treatments are also identified
The 1st European Day GRIN2B brings together families suffering from this rare illness in Barcelona
Sant Joan de Déu Hospital hosts the event, through which parents will get to know the GRIN2B research team in Barcelona led by Dr. Xavier Altafaj, IDIBELL researcher
Dr. Manel Esteller, awarded by the ECO Foundation for Excellence and Quality of Oncology
Manel Esteller, director of the epigenetics and cancer biology program at IDIBELL, ICREA researcher and professor at the University of Barcelona, has received the Award of the ECO Foundation for Excellence and Quality in Oncology, awarded last Saturday 22nd at the Spanish Royal Academy of Medicine, in Madrid. The foundation has distinguished Dr. Esteller […]
ONCE and the Bellvitge Biomedical Research Institute (IDIBELL) renew their collaboration to study hereditary dystrophies of the retina
These dystrophies are disorders with great clinical and genetic heterogeneity for which there is no cure today; 15,000 people in Spain suffer from them